Longboard Pharmaceuticals, Inc. - Common Stock (LBPH)

Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.

S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Lundbeck will buy Longboard Pharmaceuticals in a deal slated to close in the fourth quarter.

H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with bexicaserin, a potential treatment for Dravet syndrome and other neurological conditions.

Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets.

These three small-cap stocks could deliver hefty returns if the central bank cuts rates.

LBPH stock results show that Longboard Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.

You might say that this biotech stock is magnificent.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Equitrans Midstream Corporation (NYSE: ETRN) is very solid. "Good growth, good yield.

Longboard Pharmaceuticals Inc (NASDAQ: LBPH) shares are trading lower by 11.3% to $22.26 Wednesday afternoon after the company announced that it commenced a $150 million underwritten public offering and expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of s

U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy NASDAQ faced a downturn, falling 1.63% to 14,765.94. Similarly, the S&P 500 also witnessed a decline, dropping 0.57% to 4,742.83.

Longboard Pharmaceuticals is working on treatments for seizure disorders.

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to 14,743.80. The S&P 500 also fell, dropping, 0.66% to 4,738.37.